UNIVERSAL HEALTH INTERNATIONAL GROUP HOLDING LIMITED 本人╱吾等（姓名）（以正楷填寫） 地址為 ， 為大健康國際集團控股有限公司（「本公司」）股本中每股面值0.10美元的股份 （參閱附註1） 股的持有人，茲委任（姓名） ， （地址） 或（如其未能出席）（姓名） ， （地址） 或（如其未能出席）大會主席 （參閱附註2） 為本人╱吾等的代表，代表本人╱吾等出席本公司謹訂 於2025年8月19日（星期二）上午十時正假座中國遼寧省瀋陽市鐵西區北一中路14-1號2樓會議室 舉行的股東特別大會（「股東特別大會」）或其任何續會，並代表本人╱吾等於會上就所提呈的任 何決議案或動議進行投票。本人╱吾等的代表已獲授權及指示按照下文所示 （參閱附註3） 就下列 決議案投票： 2211 股東特別大會適用之代表委任表格 日期： 簽署 （附註4及5） ： 附註： 收集個人資料聲明 1. 請填上以 閣下名義登記的股份數目。如未填上股份數目，則本代表委任表格將被視為與以 閣下名義 登記的本公司股本中的所有股份有關。 2. 股東可自行委任多於一名代表，如欲作出此項委任，請將「大會主席」字樣刪 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容 而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 UNIVERSAL HEALTH INTERNATIONAL GROUP HOLDING LIMITED 普通決議案 「動議藉增設額外400,000,000股股份，將本公司法定股本由10,000,000美元（分為 100,000,000股每股0.1美元的股份（「股份」））增加至50,000,000美元（分為500,000,000股每 股0.1美元的股份）（「增加法定股本」），有關股份於發行及繳足股款後在各方面與現有已發 行股份享有同等地位並擁有權利及特權以及受本公司的組織章程大綱及組織章程細則所 載條文規限；並動議授權本公司任何一名或多名董事、公司秘書及註冊辦事處提供者為 或就執行及落實增加法定股本採取其認為屬必要、適宜或權宜的一切有關行動及事宜以 - 1 - 及簽立一切有關文件，包括但不限於根據開曼群島及香港適用的法律、規則及法規的相 關要求作出任何相關的登記及備案。」 承董事會命 2211 股東特別 ...

此乃要件 請即處理 閣下如對本通函或應採取的行動有任何疑問，應諮詢 閣下的股票經紀或其他註冊證券交易 商、銀行經理、律師、專業會計師或其他專業顧問。 閣下如已出售或轉讓名下所有大健康國際集團控股有限公司股份，應立即將本通函連同隨附代 表委任表格交予買主或承讓人，或經手買賣或轉讓的銀行、持牌證券交易商或其他代理商，以 便轉交買主或承讓人。 香港交易及結算所有限公司及香港聯合交易所有限公司對本通函的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本通函全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 UNIVERSAL HEALTH INTERNATIONAL GROUP HOLDING LIMITED | 釋義 | | 1 | | --- | --- | --- | | 董事會函件 | | 3 | | 股東特別大會通告 | | EGM-1 | 2211 建議增加法定股本 及 股東特別大會通告 本封面頁底部及本通函首頁所用詞彙與本通函「釋義」一節內所界定者分別具相同涵義。 股東特別大會將於二零二五年八月十九日（星期二）上午十時正假座中國遼寧省瀋陽市鐵西區北 一中路1 ...

大健康国际(02211)公布，董事会建议通过增设4亿股股份，将公司法定股本由1000万美元(分为1亿股公 司股份)增加至5000万美元(分为5亿股股份)，而该等股份于发行后将于各方面与现有股份享有同等地 位。 ...

智通财经APP讯，大健康国际(02211)公布，董事会建议通过增设4亿股股份，将公司法定股本由1000万 美元(分为1亿股公司股份）增加至5000万美元(分为 5亿股股份)，而该等股份于发行后将于各方面与现 有股份享有同等地位。 ...

于本公告日期，已发行80,105,955股股份，而19,894,045股股份为法定但未发行。为应对集团潜在增长及 发展并为公司于未来集资时提供更大灵活性，董事会认为增加法定股本符合公司及其股东整体利益。 格隆汇7月31日丨大健康国际(02211.HK)公告，董事会建议通过增设4亿股股份，将公司法定股本由1000 万美元(分为1亿股公司股份("股份")增加至5000万美元(分为5亿股股份)，而该等股份于发行后将于各方 面与现有股份享有同等地位。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容 而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 UNIVERSAL HEALTH INTERNATIONAL GROUP HOLDING LIMITED 2211 建議增加法定股本 茲提述大健康國際集團控股有限公司（「本公司」，連同其附屬公司，統稱為「本集團」）日 期為2025年7月4日有關根據特別授權認購新股份（「認購」）的通函。 本公司董事（「董事」）會（「董事會」）建議通過增設400,000,000股股份，將本公司法定股本 由10,000,000美元（分為100,000,000股本公司股份（「股份」）增加至50,000,000美元（分為 500,000,000股股份），而該等股份於發行後將於各方面與現有股份享有同等地位（「增加法 定股本」）。 於本公告日期，已發行80,105,955股股份，而19,894,045股股份為法定但未發行。為應對 本集團之潛在增長及發展並為本公司於未來集資時提供更大靈活性，董事會認為增加法 定股本符合本公司及其股東（ ...

Market Performance - A-shares steadily advanced this week, with the ChiNext Index reaching a new high for the year and the Shenzhen Component Index hitting a four-month high, approaching its highest point of the year [1] - Weekly trading volume increased to 7.73 trillion yuan, marking the largest weekly trading volume in three months [1] Fund Inflows - Leverage funds actively entered the market, with most industries under the Shenwan first-level industry classification seeing net buying, particularly the computer industry with over 4.4 billion yuan and the electronics industry with over 3 billion yuan [2] - The electronic, biopharmaceutical, and automotive sectors each received over 20 billion yuan in net inflows, while the non-bank financial sector saw a net outflow of over 8.3 billion yuan [2] Rare Earth Demand - The rare earth sector performed strongly, with the rare earth permanent magnet index reaching a three-and-a-half-year high [3] - Demand for rare earths is expected to grow rapidly due to advancements in humanoid robots and electric vehicles, with estimates suggesting a demand of at least 70,000 tons of neodymium-iron-boron by 2025 [3] Energy Metals - The energy metals sector, including lithium and cobalt, reached a two-year high, with lithium carbonate futures breaking 70,000 yuan/ton, marking a 20% increase from recent lows [4] - Short-term lithium salt supply may decline due to reduced exports from Chile and domestic production halts, leading to a potential price stabilization [4] Biopharmaceutical Sector - The biopharmaceutical sector saw significant gains, with the innovative drug index hitting record highs multiple times this week [6] - Notable stocks in the sector, such as Lianhuan Pharmaceutical and Aosaikang, experienced consecutive trading halts, with some stocks showing year-to-date gains exceeding 200% [6][7] Earnings Forecasts - Several pharmaceutical companies have recently forecasted substantial profit increases for the first half of 2025, with estimates suggesting net profit growth exceeding 19 times for some firms [7]

Group 1 - The core viewpoint of the news highlights the recent performance of Da Health International, noting a significant increase in its stock price despite a decline in overall revenue and profitability [1][2] - As of July 17, the stock price of Da Health International rose by 12.5% to HKD 1.44 per share, with a trading volume of 1.1399 million shares and a turnover of HKD 1.5958 million, indicating a volatility of 16.41% [1] - Over the past month, Da Health International has experienced a cumulative increase of 25.49%, while its year-to-date decline stands at 20.29%, underperforming the Hang Seng Index by 22.22% [1] Group 2 - Financial data reveals that for the year ending December 31, 2024, Da Health International is projected to achieve total revenue of HKD 441 million, representing a year-on-year decrease of 25.4%, while the net profit attributable to shareholders is expected to be a loss of HKD 8.012 million, despite a year-on-year increase of 61.72% [1] - The company has a gross profit margin of 15.95% and a debt-to-asset ratio of 43.83%, indicating its financial health and leverage [1] - Currently, there are no institutional investment ratings for Da Health International, reflecting a lack of analyst coverage [1] Group 3 - Da Health International is recognized as a leading pharmaceutical retailer and distributor in Northeast China, operating the largest retail pharmacy network in the region with 953 self-operated retail pharmacies [2] - The company serves approximately 6,500 distribution clients and benefits from a high net profit margin due to its focus on high-margin branded products, unique direct supply model, centralized procurement platform, and low operating costs [2] - Da Health International has developed a unique business model and core competitive advantages, aiming to expand its product offerings in the health sector while promoting the concept of the health industry [2]

Company Overview - Dajiankang International Group Holdings Limited is a leading pharmaceutical retailer and distributor in Northeast China, operating the largest retail pharmacy chain and being the largest private pharmaceutical distributor in the region [2] - The company has 953 retail pharmacies in Northeast China and four in Hong Kong, all self-operated, with approximately 6,500 distribution clients [2] - Dajiankang International benefits from a high net profit margin due to its focus on high-margin branded products, unique direct supply model, centralized procurement platform, and low operating costs [2] Financial Performance - As of December 31, 2024, Dajiankang International reported total revenue of 441 million yuan, a year-on-year decrease of 25.4% [1] - The company recorded a net profit attributable to shareholders of -8.01 million yuan, an increase of 61.72% year-on-year [1] - The gross profit margin stood at 15.95%, with a debt-to-asset ratio of 43.83% [1] Market Position and Valuation - The average price-to-earnings (P/E) ratio for the pharmaceutical and biotechnology industry is 6.08 times, with a median of 5.56 times [1] - Dajiankang International has a P/E ratio of 4.36 times, ranking fourth in the industry [1] - Other companies in the industry have varying P/E ratios, with Jing Tian Pharmaceutical at 0.64 times, Kingsray Biotechnology at 0.99 times, Dongrui Pharmaceutical at 2.88 times, and others [1] Recent Developments - On May 13, 2025, the company plans to issue 304.4 million new shares, representing 27.54% of the enlarged share capital, at a subscription price of 0.08 HKD per share, reflecting a discount of 1.23% from the previous closing price [3]